Intellia’s One-Time CRISPR Therapy Delivers Phase 3 Win for Hereditary Angioedema

Intellia Therapeutics reported positive topline Phase 3 HAELO results for lonvo-z (NTLA-2002), a one-time in vivo CRISPR therapy for hereditary angioedema that achieved its primary endpoint with an 87% reduction in attacks over six months, 62% attack- and therapy-free, and favorable safety; the company has initiated a rolling FDA Biologics License Application with a potential U.S. launch in the first half of 2027, marking a global first for in vivo gene editing.